SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Carver Kyle | Chief Financial Officer | 2026-07-08 | Open-market buy | 1000 | $13K |
| KIRSCH ARTHUR S | Director | 2026-07-07 | Open-market buy | 10000 | $133K |
| Drew Janice Suzann | Chief of Dev. Operations | 2026-06-22 | Option exercise 10b5-1 | 3839 | $15K |
| Drew Janice Suzann | Chief of Dev. Operations | 2026-06-22 | Option exercise 10b5-1 | 16161 | $48K |
| Drew Janice Suzann | Chief of Dev. Operations | 2026-06-22 | Open-market sell 10b5-1 | 20000 | $453K |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 2026-06-22 | Option exercise 10b5-1 | 1488 | $6K |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 2026-06-22 | Open-market sell 10b5-1 | 1488 | $33K |
| Pena Luis C. | President & CEO, Director | 2026-06-22 | Open-market sell 10b5-1 | 7438 | $169K |
| Cohen David E | Director | 2026-06-02 | Open-market sell 10b5-1 | 5456 | $110K |
| Cohen David E | Director | 2026-06-02 | Open-market sell 10b5-1 | 600 | $13K |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 2026-06-01 | Option exercise 10b5-1 | 13512 | $52K |
| Patel Jeegar Pravinkumar | Chief Scientific Officer | 2026-06-01 | Open-market sell 10b5-1 | 16687 | $379K |
| Pena Luis C. | President & CEO, Director | 2026-06-01 | Open-market sell 10b5-1 | 16787 | $382K |
| Carver Kyle | Chief Financial Officer | 2026-05-28 | Option exercise 10b5-1 | 15000 | $45K |
| Carver Kyle | Chief Financial Officer | 2026-05-28 | Open-market sell 10b5-1 | 18175 | $415K |
| Moss Gregory S. | Chief Business & Legal Officer | 2026-05-28 | Option exercise 10b5-1 | 14223 | $24K |
| Moss Gregory S. | Chief Business & Legal Officer | 2026-05-28 | Open-market sell 10b5-1 | 14223 | $325K |
| LSP 7 Cooperative UA | Director, 10% Owner | 2026-02-17 | Grant/award | 358680 | $10.0M |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-02-17 | Grant/award | 35868 | $1000K |
| Verduyn-van Weegen Felice Isabel | Director, 10% Owner | 2026-02-17 | Grant/award | 358680 | $10.0M |
Evommune announced that its Phase 2b clinical trial of EVO756 failed to meet its primary endpoint in chronic spontaneous urticaria, leading the company to cease development in this indication while continuing evaluation in atopic dermatitis and migraine. This material clinical development setback represents a significant strategic pivot affecting the company's pipeline and investor assessment of its progress.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Evommune's 2026 Annual Meeting of Stockholders held on June 2, 2026. The filing reports voting outcomes for two proposals: (1) election of directors Luis Peña and Eugene Bauer, M.D., and (2) ratification of BDO USA, P.C. as the independent registered public accounting firm. The detailed vote tallies (For, Against, Withheld, Abstain, Broker Non-Votes) are characteristic of Item 5.07 shareholder vote disclosures and are material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →